Effect of bisphosphonate and denosumab treatment on TBS in Japanese breast cancer patients with AIBL

期刊论文
发表日期：

2024年8月13日

查看全文

Emi Onuma,
Shin Saito,
Taku Tsuburai,
Hiromi Yoshikata,
Shoko Adachi,
Shinya Yamamoto,
Kazutaka Narui,
Tomonari Hayama,
Mariko Murase,
Taichi Mizushima,
Etsuko Miyagi,
Hideya Sakakibara,
Ryoko Asano

摘要

Introduction

Bisphosphonates and denosumab increase bone mineral density (BMD) for osteoporosis treatment in patients with aromatase inhibitor-associated bone loss (AIBL). This study aimed to directly compare bisphosphonates with denosumab in treating patients with AIBL and to determine the effect of denosumab on the trabecular bone score (TBS).

Materials and methods

Thirty-nine patients with AIBL receiving osteoporosis treatment (21 in the bisphosphonates group and 18 in the denosumab group) were retrospectively evaluated for changes in lumbar spine and femoral BMD, lumbar spine bone quality (assessed by TBS), and blood bone metabolic markers. The Mann–Whitney and Wilcoxon tests were used for statistical evaluation.

Results

After 24 months of treatment, the lumbar spine BMD change rate was 5.82 ± 1.10% with bisphosphonates and 10.49 ± 1.20% with denosumab, with the change rate of denosumab significantly increasing over that of bisphosphonates. The change rate in femoral BMD was 2.69 ± 1.16% with bisphosphonates and 2.95 ± 1.26% with denosumab, with no significant difference between the two groups. The rate of decrease in tartrate-resistant acid phosphatase isoform 5b was significantly higher in the denosumab group. The change rate in TBS at 24 months of treatment was 0.53 ± 1.26% in the bisphosphonates group and 1.08 ± 1.33% in the denosumab group, with no significant difference between the two groups. After 24 months, TBS remained stable.

Conclusion

Both bisphosphonates and denosumab may increase BMD, improve bone metabolism, and inhibit bone quality loss in patients with AIBL.